Pelthos (PTHS) Q4 2025 earnings review
Volume Explodes, But Discounts Bite Into Revenue
Pelthos finished its first two quarters as a commercial entity with blistering volume growth: ZELSUVMI dispensed units rocketed 129% sequentially in Q4. However, the top line told a different story, with net product revenue growing only 28% to $9.1 million. This divergence exposes a severe normalization in Gross-to-Net (GTN) discounts, confirming management's prior warnings. Below the line, a $15.0 million non-cash hit tied to convertible debt dragged GAAP Net Loss down to $21.7 million, completely masking the fact that core operational cash burn is actually reversing—Adjusted EBITDA loss improved 22% sequentially.
🐂 Bull Case
The market is hungry for an at-home Molluscum solution. Reaching 6,232 dispensed units and 2,712 unique prescribers in just the second quarter of commercialization proves the demand thesis is entirely correct.
Despite a 129% jump in product volume, SG&A actually declined 6% sequentially to $18.5 million. The initial 50-person sales force is already driving massive volume without requiring linear expense growth.
🐻 Bear Case
As expected, the highly favorable GTN from Q3 evaporated as commercial contracts and copay cards took effect. The massive lag between volume growth and revenue growth means the company is making significantly less cash per prescription.
A $15 million fair value adjustment on a newly issued $18 million convertible note is alarming. While non-cash, it highlights how expensive and dilutive this growth capital could ultimately become for common shareholders.
⚖️ Verdict: ⚪
Cautiously Optimistic. The underlying commercial execution is flawless—doctors are prescribing the drug rapidly. If management can stabilize the revenue yield per unit and integrate the new M&A assets without blowing up SG&A, the path to profitability is clear.
Key Themes
GTN Normalization Crushes Revenue per Unit
The most glaring red flag in this report is the massive spread between unit growth and revenue growth. In Q3, 2,716 units generated $7.1 million (roughly $2,618 per unit). In Q4, 6,232 units generated $9.1 million (roughly $1,459 per unit). This decelerating yield is a direct result of GTN discounts stabilizing into the mid-to-high 30% range as commercial payer rebates and copay assistance programs kick in. Volume must remain exceptionally high to offset this math.
The Nitricil Platform Proves Its Worth
The technological innovation underlying ZELSUVMI—the Nitricil platform allowing for stable, at-home topical application of berdazimer—is actively shifting the standard of care away from painful, destructive in-office procedures. With a complete 12-week clearance rate observed in trials, the technology is driving high prescriber confidence, evidenced by nearly 3,000 unique doctors adopting it in under six months.
Synergistic Portfolio Acquisitions
Management completed the acquisitions of XEPI (impetigo) and XEGLYZE (head lice). This is a textbook roll-up strategy: push three complementary pediatric dermatology products through a single, recently expanded 64-person sales force. By layering these into the bag for late 2026 and early 2027 launches, Pelthos aims to aggressively expand top-line revenue with de minimis additions to SG&A.
Seasonal Macro Headwinds
Management cited a 'seasonal reduction of patients seeking MC treatment during the fourth quarter.' Because ZELSUVMI is an acute medication requiring an initial in-office pediatric visit, the holiday season naturally suppressed patient flow. While unit volume still grew immensely, this macro seasonality proves that future Q4s will structurally lag Q3 back-to-school peaks.
Below-The-Line Earnings Volatility
The capital structure is causing extreme noise. GAAP net loss deteriorated from $16.2 million in Q3 to $21.7 million in Q4 strictly due to a $15.0 million charge for the change in fair value of the newly issued convertible debt. Coupled with a $6.9 million tax benefit, the bottom line is completely detached from operating realities. Investors must focus purely on Adjusted EBITDA to gauge true cash burn.
Sales Force Expansion Completed
The company fully executed its plan to expand the nationwide sales force from 50 to 64 representatives. This moves Pelthos into previously uncovered major metropolitan territories. With the initial 50 reps reportedly covering their own costs within 9 weeks, this expansion should serve as an accelerating driver for prescriptions heading into 2026.
Other KPIs
Reversing. This represents a 22% sequential improvement from the $11.5 million loss in Q3. It strips out the $15 million convertible debt charge, stock-based compensation, and the $6.9 million tax benefit, providing the clearest picture of core operational burn. The improvement proves the company is beginning to scale.
Stable. GAAP COGS was reported at $1.7 million, but this was heavily inflated by non-cash fair value inventory step-ups tied to the corporate merger. True underlying Adjusted COGS was virtually negligible at roughly $118,000, underscoring the massive gross margin potential of this topical gel once accounting noise clears.
The company ended Q4 with $18.0 million in cash. However, in January 2026, they drew $30.0 million from a new senior secured term loan with Horizon Technology Finance. This combined liquidity ensures they have the runway necessary to fund the upcoming XEPI and XEGLYZE launches without immediate dilutive equity raises.
Guidance
Accelerating. Management explicitly guided that personnel expenses will rise by approximately $1 million per quarter in 2026. This is driven by the recent 14-person sales team expansion and minor headcount additions required to prepare for the XEPI and XEGLYZE commercial launches.
Accelerating. While management refused to provide a specific dollar target, they stated anticipation for 'strong continued growth' in 2026. Given the expanded sales force and Q4 momentum exiting the year, sequential growth is highly probable, though it will be battling against a higher GTN base.
Management expects to launch XEPI (impetigo) in late 2026 and XEGLYZE (head lice) in the first half of 2027. These timelines dictate that FY26 revenue will still be entirely dependent on ZELSUVMI's performance.
Key Questions
The Gross-to-Net Floor
Net revenue per unit dropped roughly 44% sequentially. Where exactly does management see GTN bottoming out in 2026 now that commercial contracts are largely in place?
Debt Covenants and Restrictions
With the new $30 million secured term loan from Horizon and the $18 million convertible note, what specific revenue or cash covenants are in place that could constrain operating flexibility?
Refill Dynamics
We are now two quarters into the launch. What is the actual data showing regarding average units prescribed per patient? Are patients clearing the infection with 1 unit, or requiring the 2-3 unit cycle?
XEPI Relaunch Strategy
Since XEPI was previously launched and struggled under prior ownership, exactly what marketing angle or pricing strategy will Pelthos change to ensure it succeeds this time?